Irritable bowel syndrome: A gut microbiota-related disorder?

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 312, Issue 1, 2016, Pages G52-G62

  Bhattarai, Yogesh ^a   Muniz Pedrogo, David A ^a   Kashyap, Purna C ^a  

^a MAYO CLINIC   (United States)

Author keywords

GBA; Gut brain axis; Gut microbiota; IBS; Irritable bowel syndrome; VH; Visceral hypersensitivity

Indexed keywords

ANTIBIOTIC AGENT;

BIOINFORMATICS; DIET; GASTROINTESTINAL MOTILITY; GUT BRAIN AXIS; HUMAN; HYPERSENSITIVITY; IMMUNOSTIMULATION; INTESTINE FLORA; IRRITABLE COLON; NEXT GENERATION SEQUENCING; NONHUMAN; PATHOPHYSIOLOGY; PERMEABILITY BARRIER; PERSONAL EXPERIENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STRESS; VISCERAL HYPERSENSITIVITY; ANIMAL; HYPERALGESIA; MICROBIOLOGY; PHYSIOLOGY;

ANIMALS; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL MOTILITY; HUMANS; HYPERALGESIA; IRRITABLE BOWEL SYNDROME;

EID: 85009814751     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00338.2016     Document Type: Review

References (149)

1. Acosta A, Camilleri M, Shin A, Linker Nord S, O’Neill J, Gray AV, Lueke AJ, Donato LJ, Burton DD, Szarka LA, Zinsmeister AR, Golden PL, Fodor A. Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome. Clin Transl Gastroenterol 7: e173, 2016. doi:10.1038/ctg.2016.32.
2. Agrawal A, Houghton LA, Morris J, Reilly B, Guyonnet D, Goupil Feuillerat N, Schlumberger A, Jakob S, Whorwell PJ. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 29: 104-114, 2009. doi:10.1111/j.1365-2036.2008.03853.x.
3. Ait-Belgnaoui A, Durand H, Cartier C, Chaumaz G, Eutamene H, Ferrier L, Houdeau E, Fioramonti J, Bueno L, Theodorou V. Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats. Psychoneuroendocrinology 37: 1885-1895, 2012. doi:10.1016/j.psyneuen.2012.03.024.
4. Anitha M, Vijay-Kumar M, Sitaraman SV, Gewirtz AT, Srinivasan S. Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling. Gastroenterology 143: 1006-16.e4, 2012. doi:10.1053/j.gastro.2012.06.034.
5. Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, Li Y, Xia Y, Xie H, Zhong H, Khan MT, Zhang J, Li J, Xiao L, Al-Aama J, Zhang D, Lee YS, Kotowska D, Colding C, Tremaroli V, Yin Y, Bergman S, Xu X, Madsen L, Kristiansen K, Dahlgren J, Wang J, Jun W. Dynamics and stabilization of the human gut micro- biome during the first year of life. Cell Host Microbe 17: 690-703, 2015. doi:10.1016/j.chom.2015.04.004.
6. Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG, Lyte M. Exposure to a social stressor alters the structure of the intestinal micro- biota: implications for stressor-induced immunomodulation. Brain Behav Immun 25: 397-407, 2011. doi:10.1016/j.bbi.2010.10.023.
7. Bailey MT, Lubach GR, Coe CL. Prenatal stress alters bacterial colonization of the gut in infant monkeys. J Pediatr Gastroenterol Nutr 38: 414-421, 2004. doi:10.1097/00005176-200404000-00009.
8. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica 5: 185-194, 1982.
9. Bangsgaard Bendtsen KM, Krych L, Sørensen DB, Pang W, Nielsen DS, Josefsen K, Hansen LH, Sørensen SJ, Hansen AK. Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse. PLoS One 7: e46231, 2012. doi:10.1371/journal.pone.0046231.
10. Barbara G, Feinle-Bisset C, Ghoshal UC, Quigley EM, Santos J, Vanner S, Vergnolle N, Zoetendal EG. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology 150: 1305-1318.e8, 2016. doi:10.1053/j.gastro.2016.02.028.
11. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syn- drome. Gastroenterology 126: 693-702, 2004. doi:10.1053/j.gastro.2003.11.055.
12. Bassotti G, Villanacci V, Antonelli E, Morelli A, Salerni B. Enteric glial cells: new players in gastrointestinal motility? Lab Invest 87: 628-632, 2007. doi:10.1038/labinvest.3700564.
13. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaële N, Antonietti M, Lecleire S, Zalar A, Gourcerol G, Leroi AM, Déchelotte P, Coëffier M, Ducrotté P. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One 7: e42777, 2012. doi:10.1371/journal.pone.0042777.
14. Benson AK, Kelly SA, Legge R, Ma F, Low SJ, Kim J, Zhang M, Oh PL, Nehrenberg D, Hua K, Kachman SD, Moriyama EN, Walter J, Peterson DA, Pomp D. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl Acad Sci USA 107: 18933-18938, 2010. doi:10.1073/pnas.1007028107.
15. Bezirtzoglou E, Tsiotsias A, Welling GW. Microbiota profile in feces of breast- and formula-fed newborns by using fluorescence in situ hybridization (FISH). Anaerobe 17: 478-482, 2011. doi:10.1016/j.anaerobe.2011.03.009.
16. Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H, Simrén M. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology 149: 1399-1407.e2, 2015. doi:10.1053/j.gastro.2015.07.054.
17. Bradford K, Shih W, Videlock EJ, Presson AP, Naliboff BD, Mayer EA, Chang L. Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol 10: 385-390.e1-3, 2012. doi:10.1016/j.cgh.2011.12.018.
18. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 106: 329-336, 2011. doi:10.1038/ajg.2010.438.
19. Camilleri M, Gorman H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil 19: 545-552, 2007. doi:10.1111/j.1365-2982.2007.00925.x.
20. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 6: 71-80, 2014. doi:10.2147/CLEP.S40245.
21. Cenac N. Protease-activated receptors as therapeutic targets in visceral pain. Curr Neuropharmacol 11: 598-605, 2013. doi:10.2174/1570159X113119990039.
22. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 122: 1778-1783, 2002. doi:10.1053/gast.2002.33579.
23. Chan CL, Facer P, Davis JB, Smith GD, Egerton J, Bountra C, Williams NS, Anand P. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 361: 385-391, 2003. doi:10.1016/S0140-6736(03)12392-6.
24. Chang FY, Lu CL, Chen TS. The current prevalence of irritable bowel syndrome in Asia. J Neurogastroenterol Motil 16: 389-400, 2010. doi:10.5056/jnm.2010.16.4.389.
25. Chang L, Toner BB, Fukudo S, Guthrie E, Locke GR, Norton NJ, Sperber AD. Gender, age, society, culture, and the patient’s perspective in the functional gastrointestinal disorders. Gastroenterology 130: 1435-1446, 2006. doi:10.1053/j.gastro.2005.09.071.
26. Creed F, Ratcliffe J, Fernandes L, Palmer S, Rigby C, Tomenson B, Guthrie E, Read N, Thompson DG; North of England IBS Research Group. Outcome in severe irritable bowel syndrome with and without accompanying depressive, panic and neurasthenic disorders. Br J Psychiatry 186: 507-515, 2005. doi:10.1192/bjp.186.6.507.
27. Crouzet L, Gaultier E, Del’Homme C, Cartier C, Delmas E, Dapoigny M, Fioramonti J, Bernalier-Donadille A. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil 25: e272-e282, 2013. doi: 10.1111/nmo.12103.
28. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13: 701-712, 2012. doi:10.1038/nrn3346.
29. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505: 559-563, 2014. doi:10.1038/nature12820.
30. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 107: 14691-14696, 2010. doi:10.1073/pnas.1005963107.
31. Dey N, Soergel DA, Repo S, Brenner SE. Association of gut microbiota with post-operative clinical course in Crohn’s disease. BMC Gastroenterol 13: 131, 2013. doi:10.1186/1471-230X-13-131.
32. Dey N, Wagner VE, Blanton LV, Cheng J, Fontana L, Haque R, Ahmed T, Gordon JI. Regulators of gut motility revealed by a gnotobiotic model of diet-microbiome interactions related to travel. Cell 163: 95-107, 2015. doi:10.1016/j.cell.2015.08.059.
33. Dinan TG, Stilling RM, Stanton C, Cryan JF. Collective unconscious: how gut microbes shape human behavior. J Psychiatr Res 63: 1-9, 2015. doi:10.1016/j.jpsychires.2015.02.021.
34. Dlugosz A, Nowak P, D’Amato M, Mohammadian Kermani G, Nyström J, Abdurahman S, Lindberg G. Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea- predominant irritable bowel syndrome. Neurogastroenterol Motil 27: 1747-1754, 2015. doi:10.1111/nmo.12670.
35. Dohrman A, Miyata S, Gallup M, Li JD, Chapelin C, Coste A, Escudier E, Nadel J, Basbaum C. Mucin gene (MUC 2 and MUC 5AC) upregulation by Gram-positive and Gram-negative bacteria. Biochim Biophys Acta 1406: 251-259, 1998. doi:10.1016/S0925-4439(98)00010-6.
36. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, Knight R. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA 107: 11971-11975, 2010. doi:10.1073/pnas.1002601107.
37. Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, Maubert M, Grondin V, Jouet P, Bouhassira D, Seksik P, Sokol H, Coffin B, Sabaté JM. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 24: 513-520, 2012. doi:10.1111/j.1365-2982.2012.01893.x.
38. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC. Abnormal intestinal permeability in subgroups of diarrhea- predominant irritable bowel syndromes. Am J Gastroenterol 101: 1288-1294, 2006. doi:10.1111/j.1572-0241.2006.00672.x.
39. Ferrer M, Martins dos Santos VA, Ott SJ, Moya A. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut Microbes 5: 64-70, 2014. doi:10.4161/gmic.27128.
40. Goodrich JK, Davenport ER, Beaumont M, Jackson MA, Knight R, Ober C, Spector TD, Bell JT, Clark AG, Ley RE. Genetic determinants of the gut microbiome in UK twins. Cell Host Microbe 19: 731-743, 2016. doi:10.1016/j.chom.2016.04.017.
41. Gwee KA, Lu CL, Ghoshal UC. Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J Gastroenterol Hepatol 24: 1601-1607, 2009. doi:10.1111/j.1440-1746.2009.05984.x.
42. Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 64: 93-100, 2015. doi:10.1136/gutjnl-2014-307264.
43. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 146: 67-75.e5, 2014. doi:10.1053/j.gastro.2013.09.046.
44. Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastroenterol 20: 2470-2481, 2014. doi:10.3748/wjg.v20.i10.2470.
45. Hughes PA, Harrington AM, Castro J, Liebregts T, Adam B, Grasby DJ, Isaacs NJ, Maldeniya L, Martin CM, Persson J, Andrews JM, Holtmann G, Blackshaw LA, Brierley SM. Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes. Gut 62: 1456-1465, 2013. doi:10.1136/gutjnl-2011-301856.
46. Hughes PA, Zola H, Penttila IA, Blackshaw LA, Andrews JM, Krumbiegel D. Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? Am J Gastroenterol 108: 1066-1074, 2013. doi:10.1038/ajg.2013.120.
47. Husain N, Chaudhry IB, Jafri F, Niaz SK, Tomenson B, Creed F. A population-based study of irritable bowel syndrome in a non-Western population. Neurogastroenterol Motil 20: 1022-1029, 2008. doi:10.1111/j.1365-2982.2008.01143.x.
48. Jalanka J, Salonen A, Fuentes S, de Vos WM. Microbial signatures in post-infectious irritable bowel syndrome-toward patient stratification for improved diagnostics and treatment. Gut Microbes 6: 364-369, 2015. doi:10.1080/19490976.2015.1096486.
49. Jeffery IB, O’Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61: 997-1006, 2012. doi:10.1136/gutjnl-2011-301501.
50. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 156: 3216-3223, 2010. doi:10.1099/mic.0.040618-0.
51. Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, Wang W, Tang W, Tan Z, Shi J, Li L, Ruan B. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun 48: 186-194, 2015. doi:10.1016/j.bbi.2015.03.016.
52. Jones RC III, Xu L, Gebhart GF. The mechanosensitivity of mouse colon afferent fibers and their sensitization by inflammatory mediators require transient receptor potential vanilloid 1 and acid-sensing ion channel 3. J Neurosci 25: 10981-10989, 2005. doi:10.1523/JNEUROSCI.0703-05.2005.
53. Kabouridis PS, Lasrado R, McCallum S, Chng SH, Snippert HJ, Clevers H, Pettersson S, Pachnis V. Microbiota controls the homeostasis of glial cells in the gut lamina propria. Neuron 85: 289-295, 2015. doi:10.1016/j.neuron.2014.12.037.
54. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 22: 387-394, 2005. doi:10.1111/j.1365-2036.2005.02579.x.
55. Kashyap PC, Marcobal A, Ursell LK, Larauche M, Duboc H, Earle KA, Sonnenburg ED, Ferreyra JA, Higginbottom SK, Million M, Tache Y, Pasricha PJ, Knight R, Farrugia G, Sonnenburg JL. Complex interactions among diet, gastrointestinal transit, and gut micro- biota in humanized mice. Gastroenterology 144: 967-977, 2013. doi:10.1053/j.gastro.2013.01.047.
56. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133: 24-33, 2007. doi:10.1053/j.gastro.2007.04.005.
57. Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci 9: 392, 2015. doi:10.3389/fncel.2015.00392.
58. Kerckhoffs AP, Ben-Amor K, Samsom M, van der Rest ME, de Vogel J, Knol J, Akkermans LM. Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome. J Med Microbiol 60: 236-245, 2011. doi:10.1099/jmm.0.022848-0.
59. Kerckhoffs AP, Samsom M, van der Rest ME, de Vogel J, Knol J, Ben-Amor K, Akkermans LM. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 15: 2887-2892, 2009. doi:10.3748/wjg.15.2887.
60. Khachatryan ZA, Ktsoyan ZA, Manukyan GP, Kelly D, Ghazaryan KA, Aminov RI. Predominant role of host genetics in controlling the composition of gut microbiota. PLoS One 3: e3064, 2008. doi:10.1371/journal.pone.0003064.
61. Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG. The Saarela M, Korpela R, Palva A. Analysis of the fecal microbiota of effect of a multispecies probiotic mixture on the symptoms and fecal irritable bowel syndrome patients and healthy controls with real-time microbiota in diarrhea-dominant irritable bowel syndrome: a random- PCR. Am J Gastroenterol 100: 373-382, 2005. doi:10.1111/j.1572-0241.
62. Knowles SR, Nelson EA, Palombo EA. Investigating the role of perceived stress on bacterial flora activity and salivary cortisol secretion: a possible mechanism underlying susceptibility to illness. Biol Psychol 77: 132-137, 2008. doi:10.1016/j.biopsycho.2007.09.010.
63. Koloski NA, Jones M, Weltman M, Kalantar J, Bone C, Gowryshankar A, Walker MM, Talley NJ. Identification of early environmental risk factors for irritable bowel syndrome and dyspepsia. Neurogastroenterol Motil 27: 1317-1325, 2015. doi:10.1111/nmo.12626.
64. Krogius-Kurikka L, Lyra A, Malinen E, Aarnikunnas J, Tuimala J, Paulin L, Mäkivuokko H, Kajander K, Palva A. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 9: 95, 2009. doi:10.1186/1471-230X-9-95.
65. Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Natividad JM, Brot L, Taleb S, Couturier-Maillard A, Nion-Larmurier I, Merabtene F, Seksik P, Bourrier A, Cosnes J, Ryffel B, Beaugerie L, Launay JM, Langella P, Xavier RJ, Sokol H. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med 22: 598-605, 2016. doi:10.1038/nm.4102.
66. Lembo A, Zaman M, Jones M, Talley NJ. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment Pharmacol Ther 25: 1343-1350, 2007. doi:10.1111/j.1365-2036.2007.03326.x.
67. Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 121: 799-804, 2001. doi:10.1053/gast.2001.27995.
68. Levy RL, Whitehead WE, Von Korff MR, Feld AD. Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol 95: 451-456, 2000. doi:10.1111/j.1572-0241.2000.01766.x.
69. Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA. Mucins in the mucosal barrier to infection. Mucosal Immunol 1: 183-197, 2008. doi:10.1038/mi.2008.5.
70. Locke GR III, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ III. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 75: 907-912, 2000. doi:10.4065/75.9.907.
71. Locke GR III, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ. Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am J Gastroenterol 95: 157-165, 2000. doi:10.1111/j.1572-0241.2000.01678.x.
72. Lutgendorff F, Akkermans LM, Söderholm JD. The role of microbiota and probiotics in stress-induced gastro-intestinal damage. Curr Mol Med 8: 282-298, 2008. doi:10.2174/156652408784533779.
73. Lyra A, Krogius-Kurikka L, Nikkilä J, Malinen E, Kajander K, Kurikka K, Korpela R, Palva A. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. BMC Gastroenterol 10: 110, 2010. doi:10.1186/1471-230X-10-110.
74. Lyra A, Rinttilä T, Nikkilä J, Krogius-Kurikka L, Kajander K, Malinen E, Mättö J, Mäkelä L, Palva A. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol 15: 5936-5945, 2009. doi:10.3748/wjg.15.5936.
75. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 52: 827-833, 2003. doi:10.1136/gut.52.6.827.
76. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol Gastronintest Physiol 276: G941-G950, 1999.
77. Malinen E, Krogius-Kurikka L, Lyra A, Nikkilä J, Jääskeläinen A, Rinttilä T, Vilpponen-Salmela T, von Wright AJ, Palva A. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J Gastroenterol 16: 4532-4540, 2010. doi:10.3748/wjg.v16.i36.4532.
78. Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100: 373-382, 2005. doi:10.1111/j.1572-0241.2005.40312.x.
79. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 55: 205-211, 2006. doi:10.1136/gut.2005.073817.
80. Martens EC, Lowe EC, Chiang H, Pudlo NA, Wu M, McNulty NP, Abbott DW, Henrissat B, Gilbert HJ, Bolam DN, Gordon JI. Recognition and degradation of plant cell wall polysaccharides by two human gut symbionts. PLoS Biol 9: e1001221, 2011. doi:10.1371/journal.pbio.1001221.
81. Maxwell PR, Rink E, Kumar D, Mendall MA. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 97: 104-108, 2002. doi:10.1111/j.1572-0241.2002.05428.x.
82. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122: 107-118, 2005. doi:10.1016/j.cell.2005.05.007.
83. McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 33: 1045-1052, 2011. doi:10.1111/j.1365-2036.2011.04624.x.
84. McMurtry VE, Gupta RW, Tran L, Blanchard EE IV, Penn D, Taylor CM, Ferris MJ. Bacterial diversity and Clostridia abundance decrease with increasing severity of necrotizing enterocolitis. Microbiome 3: 11, 2015. doi:10.1186/s40168-015-0075-8.
85. Mendall MA, Kumar D. Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur J Gastroenterol Hepatol 10: 59-62, 1998. doi:10.1097/00042737-199801000-00011.
86. Michail S, Durbin M, Turner D, Griffiths AM, Mack DR, Hyams J, Leleiko N, Kenche H, Stolfi A, Wine E. Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis 18: 1799-1808, 2012. doi:10.1002/ibd.22860.
87. Michl T, Jocic M, Heinemann A, Schuligoi R, Holzer P. Vagal afferent signaling of a gastric mucosal acid insult to medullary, pontine, thalamic, hypothalamic and limbic, but not cortical, nuclei of the rat brain. Pain 92: 19-27, 2001. doi:10.1016/S0304-3959(00)00467-X.
88. Mohammed I, Cherkas LF, Riley SA, Spector TD, Trudgill NJ. Genetic influences in irritable bowel syndrome: a twin study. Am J Gastroenterol 100: 1340-1344, 2005. doi:10.1111/j.1572-0241.2005.41700.x.
89. Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome-etiology, prevalence and consequences. Eur J Clin Nutr 60: 667-672, 2006. doi:10.1038/sj.ejcn.1602367.
90. Morris-Yates A, Talley NJ, Boyce PM, Nandurkar S, Andrews G. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol 93: 1311-1317, 1998. doi:10.1111/j.1572-0241.1998.440_j.x.
91. Muller PA, Koscsó B, Rajani GM, Stevanovic K, Berres ML, Hashimoto D, Mortha A, Leboeuf M, Li XM, Mucida D, Stanley ER, Dahan S, Margolis KG, Gershon MD, Merad M, Bogunovic M. Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. Cell 158: 300-313, 2014. doi:10.1016/j.cell.2014.04.050.
92. Nanda R, James R, Smith H, Dudley CR, Jewell DP. Food intolerance and the irritable bowel syndrome. Gut 30: 1099-1104, 1989. doi:10.1136/gut.30.8.1099.
93. Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 298: G807-G819, 2010. doi:10.1152/ajpgi.00243.2009.
94. O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128: 541-551, 2005. doi:10.1053/j.gastro.2004.11.050.
95. O’Mahony SM, Marchesi JR, Scully P, Codling C, Ceolho AM, Quigley EM, Cryan JF, Dinan TG. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry 65: 263-267, 2009. doi:10.1016/j.biopsych.2008.06.026.
96. O’Sullivan A, Farver M, Smilowitz JT. The influence of early infantfeeding ractices on the intestinal microbiome and body composition in infants. Nutr Metab Insights 8, Suppl 1: 1-9, 2015. doi:10.4137/NMI.S29530.
97. Pace F, Zuin G, Di Giacomo S, Molteni P, Casini V, Fontana M, Porro GB. Family history of irritable bowel syndrome is the major determinant of persistent abdominal complaints in young adults with a history of pediatric recurrent abdominal pain. World J Gastroenterol 12: 3874-3877, 2006. doi:10.3748/wjg.v12.i24.3874.
98. Patel RM, Myers LS, Kurundkar AR, Maheshwari A, Nusrat A, Lin PW. Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am J Pathol 180: 626-635, 2012. doi:10.1016/j.ajpath.2011.10.025.
99. Peng L, He Z, Chen W, Holzman IR, Lin J. Effects of butyrate on ntestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 61: 37-41, 2007. doi:10.1203/01.pdr.0000250014.92242.f3.
100. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139: 1619-1625, 2009. doi:10.3945/jn.109.104638.
101. Perez-Burgos A, Wang L, McVey Neufeld KA, Mao YK, Ahmadzai M, Janssen LJ, Stanisz AM, Bienenstock J, Kunze WA. The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938. J Physiol 593: 3943-3957, 2015. doi:10.1113/JP270229.
102. Pérez-Cobas AE, Gosalbes MJ, Friedrichs A, Knecht H, Artacho A, Eismann K, Otto W, Rojo D, Bargiela R, von Bergen M, Neulinger SC, Däumer C, Heinsen FA, Latorre A, Barbas C, Seifert J, dos Santos VM, Ott SJ, Ferrer M, Moya A. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut 62: 1591-1601, 2013. doi:10.1136/gutjnl-2012-303184.
103. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP, Group TS; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364: 22-32, 2011. doi:10.1056/NEJMoa1004409.
104. Plöger S, Stumpff F, Penner GB, Schulzke JD, Gäbel G, Martens H, Shen Z, Günzel D, Aschenbach JR. Microbial butyrate and its role for barrier function in the gastrointestinal tract. Ann N Y Acad Sci 1258: 52-59, 2012. doi:10.1111/j.1749-6632.2012.06553.x.
105. Pozuelo M, Panda S, Santiago A, Mendez S, Accarino A, Santos J, Guarner F, Azpiroz F, Manichanh C. Reduction of butyrate- and methane-producing microorganisms in patients with irritable bowel syndrome. Sci Rep 5: 12693, 2015. doi:10.1038/srep12693.
106. Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141: 1792-1801, 2011. doi:10.1053/j.gastro.2011.07.043.
107. Rajilić-Stojanović M, Jonkers DM, Salonen A, Hanevik K, Raes J, Jalanka J, de Vos WM, Manichanh C, Golic N, Enck P, Philippou E, Iraqi FA, Clarke G, Spiller RC, Penders J. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol 110: 278-287, 2015. doi:10.1038/ajg.2014.427.
108. Rodes L, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C, Shao W, Kahouli I, Prakash S. Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol 23: 518-526, 2013. doi:10.4014/jmb.1205.05018.
109. Rothhammer V, Mascanfroni ID, Bunse L, Takenaka MC, Kenison JE, Mayo L, Chao CC, Patel B, Yan R, Blain M, Alvarez JI, Kébir H, Anandasabapathy N, Izquierdo G, Jung S, Obholzer N, Pochet N, Clish CB, Prinz M, Prat A, Antel J, Quintana FJ. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med 22: 586-597, 2016. doi:10.1038/nm.4106.
110. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9: 313-323, 2009. doi:10.1038/nri2515.
111. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 13: 35-37, 2007. doi:10.1038/nm1521.
112. Saito YA. The role of genetics in IBS. Gastroenterol Clin North Am 40: 45-67, 2011. doi:10.1016/j.gtc.2010.12.011.
113. Saito YA, Schoenfeld P, Locke GR III. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 97: 1910-1915, 2002.
114. Sansone RA, Sansone LA. Irritable bowel syndrome: relationships with abuse in childhood. Innov Clin Neurosci 12: 34-37, 2015.
115. Santos J, Yang PC, Söderholm JD, Benjamin M, Perdue MH. Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat. Gut 48: 630-636, 2001. doi:10.1136/gut.48.5.630.
116. Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, Weidler EM, Qin X, Coarfa C, Milosavljevic A, Petrosino JF, Highlander S, Gibbs R, Lynch SV, Shulman RJ, Versalovic J. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 141: 1782-1791, 2011. doi:10.1053/j.gastro.2011.06.072.
117. Schmulson M, Pulido-London D, Rodriguez O, Morales-Rochlin N, Martinez-García R, Gutierrez-Ruiz MC, López-Alvarenga JC, Robles-Díaz G, Gutiérrez-Reyes G. Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. Am J Gastroenterol 107: 747-753, 2012. doi:10.1038/ajg.2011.484.
118. Schoepfer AM, Schaffer T, Seibold-Schmid B, Müller S, Seibold F. Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 20: 1110-1118, 2008. doi:10.1111/j.1365-2982.2008.01166.x.
119. Schreiber J, Chapman KA, Summar ML, Ah Mew N, Sutton VR, MacLeod E, Stagni K, Ueda K, Franks J, Island E, Matern D, Peña L, Smith B, Urv T, Venditti C, Chakarapani A, Gropman AL. Neurologic considerations in propionic acidemia. Mol Genet Metab 105: 10-15, 2012. doi:10.1016/j.ymgme.2011.10.003.
120. Scully P, McKernan DP, Keohane J, Groeger D, Shanahan F, Dinan TG, Quigley EM. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 105: 2235-2243, 2010. doi:10.1038/ajg.2010.159.
121. Si JM, Yu YC, Fan YJ, Chen SJ. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 10:1802-1805, 2004. doi:10.3748/wjg.v10.i12.1802.
122. Smirnova MG, Guo L, Birchall JP, Pearson JP. LPS up-regulates mucin and cytokine mRNA expression and stimulates mucin and cytokine secretion in goblet cells. Cell Immunol 221: 42-49, 2003. doi:10.1016/S0008-8749(03)00059-5.
123. Sommer F, Bäckhed F. The gut microbiota-masters of host development and physiology. Nat Rev Microbiol 11: 227-238, 2013. doi:10.1038/nrmicro2974.
124. Soret R, Chevalier J, De Coppet P, Poupeau G, Derkinderen P, Segain JP, Neunlist M. Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. Gastroenterology 138: 1772-1782, 2010. doi:10.1053/j.gastro.2010.01.053.
125. Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 9: 279-290, 2011. doi:10.1038/nrmicro2540.
126. Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y. Postnatal microbial colonization programs the hypothalamicpituitary- adrenal system for stress response in mice. J Physiol 558: 263-275, 2004. doi:10.1113/jphysiol.2004.063388.
127. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 1: 101-114, 2001. doi:10.1016/S1473-3099(01)00066-4.
128. Suzuki T, Yoshida S, Hara H. Physiological concentrations of shortchain fatty acids immediately suppress colonic epithelial permeability. Br J Nutr 100: 297-305, 2008. doi:10.1017/S0007114508888733.
129. Tailford LE, Crost EH, Kavanaugh D, Juge N. Mucin glycan foraging in the human gut microbiome. Front Genet 6: 81, 2015. doi:10.3389/fgene.2015.00081.
130. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 22: 512-519, 2010. doi:10.1111/j.1365-2982.2009.01427.x.
131. Tap J, Derrien M, Törnblom H, Brazeilles R, Cools-Portier S, Doré J, Störsrud S, Le Nevé B, Öhman L, Simrén M. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 152: 111-123.e8, 2016. doi:10.1053/j.gastro.2016.09.049.
132. Taverniti V, Guglielmetti S. Methodological issues in the study of intestinal microbiota in irritable bowel syndrome. World J Gastroenterol 20: 8821-8836, 2014.
133. Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol 15: 3591-3596, 2009. doi:10.3748/wjg.15.3591.
134. Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, Guyonnet D, Legrain-Raspaud S, Trotin B, Naliboff B, Mayer EA. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 144: 1394-1401, 2013. doi:10.1053/j.gastro.2013.02.043.
135. Tlaskalová-Hogenová H, Stěpánková R, Kozáková H, Hudcovic T, Vannucci L, Tuková L, Rossmann P, Hrní T, Kverka M, Zákostelsk Z, Klimešová K, Pibylová J, Bártová J, Sanchez D, Fundová P, Borovská D, Srtková D, Zídek Z, Schwarzer M, Drastich P, Funda DP. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 8: 110-120, 2011. doi:10.1038/cmi.2010.67.
136. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI. A core gut microbiome in obese and lean twins. Nature 457: 480-484, 2009. doi:10.1038/nature07540.
137. Urbanska AM, Paul A, Bhathena J, Prakash S. Suppression of tumorigenesis: modulation of inflammatory cytokines by oral administration of microencapsulated probiotic yogurt formulation. Int J Inflamm 2010: 894972, 2010. doi:10.4061/2010/894972.
138. Uusijärvi A, Bergström A, Simrén M, Ludvigsson JF, Kull I, Wickman M, Alm J, Olén O. Use of antibiotics in infancy and childhood and risk of recurrent abdominal pain-a Swedish birth cohort study. Neurogastroenterol Motil 26: 841-850, 2014. doi:10.1111/nmo.12340.
139. Van Oudenhove L, McKie S, Lassman D, Uddin B, Paine P, Coen S, Gregory L, Tack J, Aziz Q. Fatty acid-induced gut-brain signaling attenuates neural and behavioral effects of sad emotion in humans. J Clin Invest 121: 3094-3099, 2011. doi:10.1172/JCI46380.
140. Vázquez-Frias R, Gutiérrez-Reyes G, Urbán-Reyes M, Velázquez-Guadarrama N, Fortoul-van der Goes TI, Reyes-López A, Consuelo-Sánchez A. Proinflammatory and anti-inflammatory cytokine profile in pediatric patients with irritable bowel syndrome. Rev Gastroenterol Mex 80: 6-12, 2015.
141. Verdú EF, Bercik P, Verma-Gandhu M, Huang XX, Blennerhassett P, Jackson W, Mao Y, Wang L, Rochat F, Collins SM. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 55: 182-190, 2006. doi:10.1136/gut.2005.066100.
142. Villarreal AA, Aberger FJ, Benrud R, Gundrum JD. Use of broadspectrum antibiotics and the development of irritable bowel syndrome. WMJ 111: 17-20, 2012.
143. Weston AP, Biddle WL, Bhatia PS, Miner PB Jr. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 38: 1590-1595, 1993. doi:10.1007/BF01303164.
144. Whitehead WE, Crowell MD, Robinson JC, Heller BR, Schuster MM. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 33: 825-830, 1992. doi:10.1136/gut.33.6.825.
145. Winston J, Shenoy M, Medley D, Naniwadekar A, Pasricha PJ. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology 132: 615-627, 2007. doi:10.1053/j.gastro.2006.11.014.
146. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD. Linking long-term dietary patterns with gut microbial enterotypes. Science 334: 105-108, 2011. doi:10.1126/science.1208344.
147. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 146: 41-46, 2009. doi:10.1016/j.pain.2009.06.017.
148. Zoetendal EG, Akkermans AD, Akkermans-van Vliet WM, Visser JA, de Vos WM. The host genotype affects the bacterial community in the human gastronintestinal tract. Microb Ecol Health Dis 13: 129-134, 2001. doi:10.3402/mehd.v13i3.8013.
149. Zuckerman MJ, Nguyen G, Ho H, Nguyen L, Gregory GG. A survey of irritable bowel syndrome in Vietnam using the Rome criteria. Dig Dis Sci 51: 946-951, 2006. doi:10.1007/s10620-005-9005-0.